Researchers identified a protective subtype of microglia that expands as Alzheimer's disease progresses, playing a key role in clearing harmful material from the brain. The study provides insights into how the brain's immune cells change across the lifespan and throughout Alzheimer's disease, paving the way for therapies that strengthe...
Researchers at UC San Diego identified a key cellular pathway that drives brain degeneration in both Sanfilippo syndrome type A and Alzheimer's disease. The study reveals how the brain's immune cells respond to waste buildup, providing a novel target for drug development.
Researchers identified seven proteins in the blood that can help diagnose Alzheimer's disease more accurately, improving treatment choices and future research. The new blood-based tests provide a clearer picture of the disease, allowing for earlier detection and better patient outcomes.
Researchers found that middle-aged individuals with a higher frequency of nocturnal micro-awakenings are more genetically prone to develop Alzheimer’s disease. In contrast, younger adults did not show this association. The study suggests that sleep analysis could complement existing tools for early identification and prevention.
Researchers at UH College of Pharmacy are developing breakthroughs to combat sepsis, a leading cause of hospital deaths, and diseases such as Alzheimer's and sickle cell disease. A dual-action nanomedicine has shown a 100% survival rate in preclinical trials for sepsis treatment.
A study published in The Journal of Prevention of Alzheimer's Disease found that patients with early Alzheimer's disease are often not adhering to brain health recommendations, including exercise and healthy eating. Most patients pursue anti-amyloid antibody therapy but still fall short of optimal brain health guidelines.
A new hypothesis proposes that women's reproductive resilience is key to understanding longevity, with menopause representing an important inflection point in the loss of reproductive resilience. This framework challenges traditional views on aging and fertility, highlighting the importance of studying women in longevity research.
The first complete marmoset genome is now available, providing a high-quality reference for studying complex diseases like Alzheimer's. The new genome reveals variation in genes linked to Alzheimer's disease, as well as immune system genes and previously un-catalogued ribosomal DNA genes.
The Boston University-Quantitative Population Science and Healthy Cognitive Aging Research Program (BU-SHARP) aims to better understand how and why Alzheimer's disease manifests among certain populations. The center will fund pilot studies, provide technical assistance, and facilitate access to underutilized datasets.
Researchers used real human brain tissue samples to test the underlying mechanisms of deep brain stimulation. They found that brain cells became more synchronized in communicating, similar to memory formation, while altering gene expression across different types of brain cells.
A new AI triage agent will be embedded in Vanderbilt Health's EHR to quickly evaluate patients with Alzheimer's disease. The system will analyze chart information, flag missing details, and recommend referrals for priority or standard evaluation, aiming to reduce wait times from weeks to days.
A study published in Neurology found that between 70% and 85% of people with atypical Alzheimer's disease would not meet eligibility criteria for anti-amyloid treatments. The main reason for exclusion was poor performance on cognitive screening tests, particularly those assessing visual-spatial abilities or executive functioning.
A new MRI metric, PSMD, detects early white matter abnormalities in Alzheimer's disease, including in individuals with Down syndrome. This study provides insights into the early stages of Alzheimer's disease and its progression.
Researchers discovered that depression is associated with a specific area of the hippocampus, independent of Alzheimer's disease risk factors. The study found participants with depression had smaller volumes in the CA23DG region, which plays a crucial role in retrieving memories and distinguishing between similar experiences.
A new report finds that delayed discharges and poor hospital environments keep people with dementia in hospitals unnecessarily, costing £328 million annually. The study suggests community-centric approaches can reduce hospitalisations and improve care.
A study found that lower cardiac output is associated with accelerated cerebral atrophy among older adults carrying the APOE-e4 allele, a genetic risk factor for Alzheimer's disease. Lower baseline cardiac output was linked to smaller brain volumes and larger inferior lateral ventricle volumes over time in APOE-e4 carriers.
A new immunotherapy for Alzheimer's disease has shown promising results in a Phase 1 clinical trial. The treatment aims to reverse immune aging and reduce biomarkers of neuronal damage, supporting further clinical development of this innovative strategy.
The study presents a novel 3D brain tissue model that accurately replicates the complex interactions in human brain tissue with Alzheimer's disease. The model uses human stem cells to form neurons, astrocytes, and microglial cells, which exhibit key functions similar to those in a real human brain.
A new USC study uses AI to generate detailed maps of brain aging, revealing distinct patterns of neurodegeneration in specific regions. The approach sheds light on how local brain age correlates with changes in cognitive function across the lifespan.
University of Rhode Island researcher William Van Nostrand will study cerebral amyloid angiopathy (CAA) using a $1.5 million grant, aiming to elucidate disease mechanisms and identify early-stage biomarkers for this prevalent disease in the elderly population and Alzheimer's patients.
Researchers have identified a new type of brain plaque, called mitochondrial plaques, that may emerge at the earliest stages of Alzheimer's disease. These plaques contain high levels of amyloid precursor protein and can directly affect neurons, making them a potential target for new treatments.
A new $3.3 million study aims to investigate how people perceive cognitive changes as they age, with a focus on identifying predictive markers for dementia. The 'worried well' - individuals with cognitive complaints but normal test results - may hold clues to early disease detection.
Researchers found two widely used blood tests accurate in detecting Alzheimer’s pathology in participants with Down syndrome. The tests, Lumipulse G p-tau217 and PrecivityAD2, offer an easier path to diagnosis for this high-risk population.
A small clinical trial found that time-restricted eating improved spatial planning and problem-solving skills, reducing errors related to memory and learning. After six months, participants who limited their daily eating window showed significant cognitive improvements compared to those maintaining a standard eating window.
Researchers used AI and single-cell technology to study the 3D genome in brain cells from individuals with Alzheimer's disease. They found increased compartment mingling, reduced gene activity, and altered brain cell organization. The study identifies 3D genome organization as a key layer of Alzheimer's biology.
A study found that brain immune cells undergo substantial remodeling in midlife, leading to chronic neuroinflammation and potential dementia risk. The research used advanced single-cell analysis techniques to analyze postmortem hippocampal tissue from 40 healthy adults.
Researchers identify a specialized lymphatic network in the brain that enables cerebrospinal fluid drainage, which declines with age but can be restored through intranasal VEGF-C delivery. This discovery provides new insights into brain waste clearance and its link to neurodegenerative disorders.
Researchers found no correlation between SuperAgers' exceptional memory and low inherited Alzheimer's disease risk. Instead, they identified unique biological and psychosocial characteristics associated with SuperAging.
A study published in PLOS Medicine found that people with dementia, mild cognitive impairment, alcohol addiction, or psychiatric disorders like schizophrenia show increased brain aging patterns. The researchers analyzed MRI data from over 45,900 controls and compared them to 2,698 patients with different brain conditions.
Researchers found that tau buildup in PSP affects brain networks involved in thinking, including the prefrontal cortex and anterior cingulate cortex. The study suggests that symptoms arise from both local tau-related damage and remote disruption of a broader cognitive network.
A new study by Sanford Burnham Prebys found that bolstering the SORLA protein can reduce tau tangle toxicity, a common culprit in Alzheimer's disease and other neurodegenerative disorders. This suggests potential as a therapeutic strategy for treating these conditions.
Research found reduced volume in areas of the brain connected to memory formation, indicating a potential link between TV watching and cognitive decline. Heavy TV viewing was associated with smaller frontal and occipital lobes and more white matter damage, even after controlling for physical activity.
Researchers discovered that senescent cells accumulate high levels of triacylglycerols and increase glycolytic activity, leading to increased lipid droplet accumulation. This finding suggests that lipid droplets may contribute to the harmful effects of senescent microglia in Alzheimer’s disease.
A blood test measuring phosphorylated tau 217 (P-tau217) can estimate an individual's risk of developing cognitive impairment over 2, 5, and 10 years. Higher P-tau217 levels are associated with increased risk of progression to cognitive impairment in cognitively unimpaired older adults.
A blood-based test for the biomarker p-tau217 has been shown to predict the risk of developing cognitive impairment due to Alzheimer's disease up to a decade earlier than previously thought. The study found that individuals with very high levels of p-tau217 had a 38% absolute risk of developing cognitive impairment over five years, and...
The meeting will explore breakthroughs in diabetes prevention and treatment, as well as innovative approaches to monitoring astronauts' health in space. Researchers will also discuss potential targets for slowing or preventing Alzheimer's disease in people with Down syndrome, and advancements in cervical cancer screening.
Researchers discovered that reducing microglial activity worsened abnormal electrical activity and increased seizure-like events in a mouse model of Alzheimer's disease. Microglia are not just drivers of inflammation but also perform important housekeeping functions to maintain healthy brain activity.
Researchers at Texas A&M University have found a way to intervene early in traumatic brain injuries using a natural, gut-derived chemical that prevents post-traumatic epilepsy from taking root. The treatment reduced brain inflammation, improved memory and mood, protected brain cells, made seizures both rarer and harder to trigger.
A new study from UT Health San Antonio found a link between long sleep hours and higher levels of an Alzheimer's-related protein in the blood. The research suggests that long sleep may reflect early neurodegenerative processes, but more sleep is not always better for brain health.
A recent clinical trial found that a combination of THC and CBD significantly reduced agitation in people with late-stage dementia. The study, which enrolled 120 participants, showed a 6.27-point reduction in mean agitation scores after 2 weeks and a sustained reduction at 12 weeks.
The University of Cincinnati launches the Center for Alzheimer's and Neurodegenerative Diseases Research (CANDR) to improve dementia prevention and treatment outcomes. CANDR aligns with UC's mission to innovate and engage locally while addressing one of the region's most pressing public health challenges.
A global consortium has developed three open-source AI tools to synthesize Alzheimer's literature, surface hidden data insights, and provide peer review feedback. The tools are designed for researchers to harness vast amounts of information toward a shared goal.
A meta-analysis of individual participant data found that amyloid PET quantitation using centiloids can accurately diagnose Alzheimer's disease. The study suggests that scans in the 11-26 Centiloid range require caution, and a positivity cutoff of around 18 Centiloids is recommended.
A clinical trial of Ceperognastat, a novel O-linked N-acetylglucosaminidase inhibitor, found no significant slowing of Alzheimer's disease progression in early symptomatic patients. The study published in JAMA suggests that Ceperognastat may not be effective in treating this stage of the disease.
A University of Houston chemist is uncovering how copper imbalances in neurons contribute to neurodegenerative diseases like Alzheimer's, Parkinson's, and ALS. The new imaging technique provides a closer look at individual protein behaviors inside living cells, giving researchers insight into the cellular pathways that fail.
A new study published in the Journal of Alzheimer's Disease estimates that dementia-related costs across 30 high-income European countries total €221 billion annually. Family caregivers carry a significant portion of this burden, providing an estimated €128 billion in unpaid care.
Amyloid clearance after amyloid-targeting therapy reduces downstream neuropathologic changes, particularly in gyral crests. Extensive amyloid clearance may be necessary for beneficial effects.
The University of California, San Francisco is launching a novel clinical trial to test a combination of therapies for the most common form of Alzheimer's disease. The trial will enroll up to 825 participants and test drugs that target both amyloid and tau proteins, with the goal of slowing disease progression.
Researchers discovered that damaged myelin generates abnormal rhythms in the sleeping brain, linked to disruptions in brain circuit stability. This finding may help design non-invasive approaches to repair myelin during sleep, improving sleep quality in patients with MS and Alzheimer's disease.
Scientists at King's College London have developed a human-safe drug that repairs DNA breaks and reduces inflammation in a mouse model of Alzheimer's disease. This approach targets multiple features of the disease simultaneously, providing a broader therapeutic strategy than previous approaches focused on individual disease hallmarks.
Researchers developed a human-safe drug that repairs DNA breaks and reduces inflammation in a mouse model of Alzheimer's disease. The approach targets multiple disease-relevant cellular pathways, providing a broader therapeutic strategy than previous approaches focused on individual disease hallmarks.
Researchers found that KCL-286 enhances DNA repair and reduces neuronal inflammation in a mouse model of Alzheimer's disease. The drug activates the retinoic acid receptor-beta pathway, promoting the expression of certain repair genes.
Research suggests alcohol interacts with Alzheimer's-related brain circuits in distinct ways, depending on the type of pathological change. Alcohol reduced communication in amyloid-beta models but increased it in tau models, highlighting an important principle in biology.
Researchers at King's College London discovered a molecule linked to chronic inflammation disrupts brain neuron formation, highlighting a pathway with therapeutic potential for conditions like Alzheimer's disease and depression. High cytokine levels trigger an 'immune alert' state, reducing new nerve cell production.
Researchers have developed a molecular imaging technology that can visualize toxic amyloid-beta oligomers, which are believed to trigger Alzheimer's disease years before symptoms appear. The technology has the potential to become next-generation PET imaging agents for Alzheimer's disease.
A new study found that BCG vaccines can modify Alzheimer's biomarkers in non-Alzheimer's participants, suggesting a potential biological explanation for the observed link between BCG vaccination and lower disease risk. The vaccine also promoted increased immune responses in healthy participants without Alzheimer's pathology.
A new Virginia Tech study finds that patterns of repetitive negative thinking can carry anxiety into deeper distress among dementia caregivers, but also suggests that mindfulness training may help identify and interrupt this progression. Researchers also found that introducing mindfulness early on can aid in managing stress before it d...
A new study links tire pollution to Alzheimer's disease through the exposure to 6PPD-quinone, a chemical formed from shaved-off tire particles. The researchers used computational methods to identify key genes that predict Alzheimer's disease and found strong binding of 6PPD-quinone to these genes.
Researchers at University of Arizona have found a promising new approach to slow fatal nerve disease ALS by blocking a small part of a key protein. The experimental drug XL20 protects nerve cells and reduces muscle weakness in mice and human nerve cells, representing a potential breakthrough.
A USC interdisciplinary team has identified a promising pathway to turn off brain inflammation before it does its damage, increasing the risk of late-onset Alzheimer's. The Norman and Mary Pattiz Foundation funding will support research on novel drug discovery, early detection, and prevention of Alzheimer's disease.